For Residents

Ketamine and serotonin syndrome: A case report

Author and Disclosure Information

 

References

There is sparse literature describing serotonin syndrome related to ketamine use. Ketamine has been shown to increase levels of glutamate in the medial prefrontal cortex. Higher levels of glutamine in turn stimulate excitatory glutamatergic neurons that project to the dorsal raphe nucleus. When stimulated, the dorsal raphe nucleus releases serotonin.6 There is also evidence that ketamine inhibits uptake of serotonin in synapses.7 These mechanisms combine to create a net increase in CNS-wide serotonin.

Ketamine is being increasingly used to treat depression and other conditions. This case report underscores the importance of considering serotonin syndrome when treating patients receiving ketamine, especially when it is used in conjunction with selective serotonin reuptake inhibitors.

Pages

Recommended Reading

Top research findings of 2018-2019 for clinical practice
MDedge Psychiatry
Suicidal while receiving treatment for breast cancer
MDedge Psychiatry
Are doctors really at highest risk for suicide?
MDedge Psychiatry
Posttraumatic stress may persist up to 9 months after pregnancy loss
MDedge Psychiatry
Risk-benefit ratio on the radar as new antidepressant therapies emerge
MDedge Psychiatry
Excessive masculinity linked to high suicide risk
MDedge Psychiatry
EEG signature predicts antidepressant response
MDedge Psychiatry
How to beat bullying in the workplace
MDedge Psychiatry
Depression, or something else?
MDedge Psychiatry
Depression in MS predicted worsening of neurologic function
MDedge Psychiatry